• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

5.610 +0.740 (+15.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
May 15, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
May 12, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
April 30, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
Examining the Future: TriSalus Life Sciences's Earnings Outlook ↗
March 26, 2025
 
Via Benzinga
News headline image
A Look Ahead: TriSalus Life Sciences's Earnings Forecast ↗
November 13, 2024
 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
May 15, 2025
 
Via Benzinga
News headline image
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic ↗
March 27, 2025
The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 
Via Stocktwits
News headline image
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
March 27, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
March 26, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
Earnings Scheduled For March 27, 2025 ↗
March 27, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
March 21, 2025
 
Via Benzinga
News headline image
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
March 06, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
3 Stocks With Robust Growth Outlooks Insiders Are Buying
February 19, 2025
Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025. 
Via MarketBeat
News headline image
TriSalus Life Sciences Announces Key Appointments to Board of Directors
February 03, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
February 03, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
January 23, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
January 09, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Announces Leadership Changes
January 08, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
November 14, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday ↗
November 11, 2024
 
Via Benzinga
News headline image
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
November 11, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
Earnings Scheduled For November 14, 2024 ↗
November 14, 2024
 
Via Benzinga
News headline image
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
November 07, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
October 31, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 14, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
October 07, 2024
 
Via Benzinga
News headline image
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
September 26, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
September 23, 2024
From TriSalus Life Sciences
Via Business Wire
News headline image
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024 ↗
August 15, 2024
TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
TriSalus Reports Q2 2024 Financial Results and Business Update
August 15, 2024
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap